Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...